A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000503:physiopathology / Q000648:ultrastructure*; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004702:Endocrine Glands / Q000503:physiopathology*; D004967:Estrogens / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000648:ultrastructure*; D013739:Testosterone / Q000097:blood
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D013739:Testosterone; D004054:Diethylstilbestrol; D007986:Luteinizing Hormone; D008525:Medroxyprogesterone